{
    "eid": "2-s2.0-85142452278",
    "title": "Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Genetics (clinical)",
            "@code": "2716",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "coagulation factor VIII",
        "haemophilia A",
        "pharmacokinetics",
        "riroctocog alfa pegol",
        "Thailand"
    ],
    "authors": [
        "Arunothai Rakmanotham",
        "Chatphatai Moonla",
        "Darintr Sosothikul"
    ],
    "citedby-count": 0,
    "ref-count": 17,
    "ref-list": [
        "Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis",
        "New therapies for hemophilia",
        "Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia",
        "WFH guidelines for the management of hemophilia",
        "Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations",
        "Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing",
        "A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management",
        "Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy",
        "Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII",
        "Personalized prophylaxis",
        "Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B",
        "When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH",
        "Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach",
        "Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT\u00ae",
        "Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A",
        "Patient powered prophylaxis: a 12-month study of individualized prophylaxis in adults with severe haemophilia A",
        "Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Hemophilia Center",
        "Ratchadaphiseksomphot Endowment Fund",
        "King Chulalongkorn Memorial Hospital",
        "Takeda Pharmaceutical Company Limited",
        "Chulalongkorn University",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}